Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Urinary Bladder Neoplasms 2Glioma 2Oligodendroglioma 1Melanoma 1Lymphoma, Follicular 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 31Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 15Biopsy 11trametinib 10dabrafenib 10fludarabine phosphate 9spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Transurethral Resection of Bladder × Clear all
NCT07288112 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Diakonos Oncology Corporation

Phase 1/2 Recruiting
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡